I couldn't agree more. I like Mach's conservative analysis. That, as a beginning, would be a blessing. By the allowance it is fairly obvious that the tech is viable and extremely important.

My thought is that there is considerable noise being made about the technology, it's potential and future reconfigurations that may be adopted to other infectious diseases. Otherwise I don't feel this would have progressed at rapidly as it did.

Final thought about the company is that they have been engaged in aggressive pursuit of the allowance, cost be damned, and that there are players that may, or are, very interested in this tech and it's future potential.

I believe that management has some well connected individuals, experts and advisor's to carry the load as it currently stands to the next level.